Clinical Trials Link
Primary Protocol Team Members
P1066 is a Phase I/II, multi-center, open-label, noncomparative intensive PK study. The study is designed to evaluate the following with respect to raltegravir use in the study population: short-term safety and tolerability; steady state plasma concentration profiles and PK parameters; and chronic dosing safety and tolerability. Duration of study treatment in Stage I and II will be 48 weeks; subjects will have the option to continue to receive the raltegravir for 5 years from initial exposure. The study will enroll approximately 120 to 160 HIV-infected children and adolescents between the ages of ≥4 weeks to <19 years.